Sun Pharma Adv. Res

Sun Pharma Advanced Research Company is a clinical-stage biopharmaceutical firm that operates with an innovation-led, research-focused business model to develop new pharmaceutical products. Its guiding vision is to consistently elevate care standards for patients across the globe by pioneering innovations in both new treatments and their delivery methods. The company specializes in creating new small molecules and biologics, strategically concentrating its research efforts in the specialized areas of oncology and immunology. Instead of direct selling, SPARC licenses its unique innovations to pharmaceutical partners, creating revenue from out-licensing agreements, royalties, and milestone-based payments. A key pipeline asset is its Antibody-Drug Conjugate, SBO-154, which targets the MUC-1 antigen for treating multiple types of cancers. The company's scientific expertise is powered by a workforce where 85% of its 316 dedicated employees are highly qualified and experienced scientists.;